DC Field | Value | Language |
dc.contributor.author | Johnson, Jisma | - |
dc.contributor.author | Dolapciu, Elena | - |
dc.date.accessioned | 2025-03-05T12:01:34Z | - |
dc.date.available | 2025-03-05T12:01:34Z | - |
dc.date.issued | 2024 | - |
dc.identifier.citation | JOHNSON, Jisma; DOLAPCIU, Elena. Malignancies in children with immunodeficiencies. In: Revista de Ştiinţe ale Sănătăţii din Moldova = Moldovan Journal of Health Sciences. 2024, vol. 11, nr. 3, anexa 2, p. 668. ISSN 2345-1467. | en_US |
dc.identifier.issn | 2345-1467 | - |
dc.identifier.uri | https://cercetare.usmf.md/sites/default/files/inline-files/MJHS_11_3_2024_anexa2__site.pdf | - |
dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/30049 | - |
dc.description.abstract | Background. Primary immunodeficiency disorders (PIDs)
are a heterogeneous group of genetic conditions characterized by impaired immune function. Recent studies have
highlighted a complex connection between PIDs and an
increased risk of malignancies. However, the underlying
mechanisms remain poorly understood. Objective of the
study. This study aims to understand the relationship between immunodeficiency and susceptibility to malignancy
by reviewing literature sources. Material and methods.
Data from online databases such as Pubmed, UpToDate, and
the National Library of Medicine were used to review the
literature examining factors associated with malignancy in
patients with PID. Results. Cancer is the second most common cause of death in PID patients. The cancer risk in PID
patients is estimated to be 4 - 25%, and some studies have reported a notable increase in standardized incidence ratios of various cancers. Non-Hodgkin lymphoma (48%) and
Hodgkin lymphoma (10% of cases) are the most common
cancers in PIDs, diagnosed often at younger ages. PID-related malignancies affect mainly ataxia-telangiectasia and
common variable immunodeficiency patients over 50% of
cases, another 30% linked to Wiskott-Aldrich syndrome,
severe combined immunodeficiency and selective IgA deficiency. Conclusions. PID patients have a higher risk of
many diverse cancers for genetic, immunological, and environmental reasons. Management is challenging, requiring
continued surveillance and individualized treatment based
on the underlying immunodeficiency and associated complications. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Instituţia Publică Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” din Republica Moldova | en_US |
dc.relation.ispartof | Revista de Științe ale Sănătății din Moldova = Moldovan Journal of Health Sciences | en_US |
dc.subject | primary immunodeficiency | en_US |
dc.subject | malignancy | en_US |
dc.subject | tumor predisposition | en_US |
dc.title | Malignancies in children with immunodeficiencies | en_US |
dc.type | Other | en_US |
Appears in Collections: | Revista de Științe ale Sănătății din Moldova : Moldovan Journal of Health Sciences 2024 Vol. 11, Issue 2
|